STAAR Surgical Reports First Quarter 2025 Results

Published on May 8, 2025
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has reported results for the first quarter ended March 28, 2025. Net sales were $42.6 million for the first quarter of 2025 compared with $77.4 million in the prior-year quarter, a 45 percent decrease that the company attributes primarily to a significant decline in China revenue, advising that purchases by the company's China distributors were minimal in the quarter as they consumed existing in-country inventory to satisfy procedural demand. The decline in first quarter net sales was partially offset by growth in other geographies, the company stated.
Continue reading on website
Other news

Topcon announces dual launch of IDHea and Cascader Limited

May 7, 2025
Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in health care, alongside Cascader Limited, which was created in partnership with Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology (IoO).

What do you say when your best friend asks for dry eye advice?

May 8, 2025
When her friend began experiencing dry eye symptoms while undergoing chemotherapy, Katherine Mastrota, OD, MS, FAAO, Dipl ABO, found herself in a unique position to provide specialized advice.